Antipsychotic medication, functional outcome and quality of life in schizophrenia: Focus on amisulpride

Current Medical Research and Opinion

Volumn 26, Issue 4, 2010, Pages 787-801

  Nuss, Philippe ^a   Tessier, Cedric ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

Amisulpride; Functional outcome; Psychometric rating scales; Quality of life; Schizophrenia

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; OLANZAPINE; RISPERIDONE; ZIPRASIDONE;

CLINICAL TRIAL; CONTROLLED STUDY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; QUALITY OF LIFE; RATING SCALE; REVIEW; SCHIZOPHRENIA; SOCIAL INTERACTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WELLBEING;

ACTIVITIES OF DAILY LIVING; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; QUALITY OF LIFE; SCHIZOPHRENIA; SULPIRIDE; TREATMENT OUTCOME;

EID: 77949500414     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903576953     Document Type: Review

References (61)

1. Awad AG, Hogan TP, Voruganti LN, et al. Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol 1995;10(Suppl. 3):123-132
2. Awad AG, Lapierre YD, Angus C, et al. Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. The Canadian Remoxipride Group. J Psychiatry Neurosci 1997; 22:244-248
3. Voruganti L, Heslegrave R, Awad AG, et al. Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability. Psychol Med 1998;28:165-172
4. Marwaha S, Johnson S, Bebbington P, et al. Correlates of subjective quality of life in people with schizophrenia: findings from the EuroSC study. J Nerv Ment Dis 2008;196:87-94
5. Heider D, Angermeyer MC, Winkler I, et al. A prospective study of quality of life in schizophrenia in three European countries. Schizophr Res 2007; 93:194-202
6. Meijer CJ, Koeter MW, Sprangers MA, et al. Predictors of general quality of life and the mediating role of health related quality of life in patients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2009;44:361-368
7. Hofer A, Kemmler G, Eder U, et al. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry 2004;65:932-939
8. Salome F, Petitjean F, Germain C, et al. [The subjective quality of life of patients with schizophrenia: influence of psychopathology and patients' expectations. A comparative study]. Encephale 2004;30:60-68
9. Meltzer HY, Burnett S, Bastani B, et al. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990;41:892-897
10. Tek C, Kirkpatrick B, Buchanan RW. A five-year followup study of deficit and nondeficit schizophrenia. Schizophr Res 2001;49:253-260
11. Yamauchi K, Aki H, Tomotake M, et al. Predictors of subjective and objective quality of life in outpatients with schizophrenia. Psychiatry Clin Neurosci 2008;62:404-411
12. Delamillieure P, Ochoa-Torres D, Vasse T, et al. The subjective quality of life in deficit and nondeficit schizophrenic patients. Eur Psychiatry 2005;20:346-348
13. Norman RM, Malla AK, Cortese L, et al. Symptoms and cognition as predictors of community functioning: a prospective analysis. Am J Psychiatry 1999; 156:400-405
14. Awad AG, Voruganti LN, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual Life Res 1997;6:21-26
15. Lindstrom E, Bingefors K. Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmacoeconomics 2000;18:106-124
16. Hellewell JS. Patients' subjective experiences of antipsychotics: clinical relevance. CNS Drugs 2002;16:457-471
17. Voruganti L, Cortese L, Oyewumi L, et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective toler-ability, side-effect profile and impact on quality of life. Schizophr Res 2000;43:135-145
18. Mortimer AM, Al-Agib AO. Quality of life in schizophrenia on conventional versus atypical antipsychotic medication: a comparative cross-sectional study. Int J Soc Psychiatry 2007;53:99-107
19. Ritsner M, Gibel A, Perelroyzen G, et al. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol 2004;24:582-591
20. Divanon F, Delamillieure P, Lehaguez A, et al. [Comparative evaluation of quality of life in patients with schizophrenia treated with conventional versus atypical neuroleptics: results of a transversal study]. Encephale 2006;32 (4 Pt 1):459-465
21. Swartz MS, Perkins DO, Stroup TS, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 2007;164:428-436
22. Haro JM, Novick D, Suarez D, et al. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol 2006;26:571-578
23. Fleischhacker WW, Keet IP, Kahn RS. The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophr Res 2005;78:147-156
24. Awad AG, Voruganti LN. New antipsychotics, compliance, quality of life, and subjective tolerability-are patients better off? Can J Psychiatry 2004; 49:297-302
25. McKeage K, Plosker GL. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs 2004;18:933-956
26. Peuskens J, Moller HJ, Puech A. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. Eur Neuropsychopharmacol 2002;12:305-310
27. Vanelle JM, Douki S. A double-blind randomised comparative trial of amisul-pride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. Eur Psychiatry 2006;21:523-530
28. Thomas P, Alptekin K, Gheorghe M, et al. Management of patients presenting with acute psychotic episodes of schizophrenia. CNS Drugs 2009;23: 193-212
29. Storosum JG, Elferink AJ, van Zwieten BJ, et al. Amisulpride: is there a treatment for negative symptoms in schizophrenia patients? Schizophr Bull 2002;28:193-201
30. Leucht S, Pitschel-Walz G, Engel RR, et al. Amisulpride, an unusual 'atypical' antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002;159:180-190
31. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41
32. Saleem P, Olie JP, Loo H. Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride. Int Clin Psychopharmacol 2002;17:1-8
33. Bobes J, Garcia-Portilla P, Saiz PA, et al. Quality of life measures in schizophrenia. Eur Psychiatry 2005;20(Suppl. 3):S313-7
34. Alonso J, Croudace T, Brown J, et al. Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study. Value Health 2009;12:536-543
35. Heinrichs RW. Verbal responses to human figure paintings: a test of the uncertainty hypothesis. Can J Psychol 1984;38:512-518
36. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995;10(Suppl. 3):133-138
37. Heinrichs DW, Hanlon TE, Carpenter Jr WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-398
38. Cramer JA, Rosenheck R, Xu W, et al. Quality of life in schizophrenia: a comparison of instruments. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Schizophr Bull 2000;26:659-666
39. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-343
40. Priebe S, Huxley P, Knight S, et al. Application and results of the Manchester Short Assessment of Quality of Life (MANSA). Int J Soc Psychiatry 1999; 45:7-12
41. Gilchrist A, Taylor M, Wright M, et al. Is olanzapine clinically effective? A naturalistic outcome survey in two hospital settings. Pharmaceut J 2002; 269:222-225
42. Jones SH, Thornicroft G, Coffey M, et al. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 1995;166:654-659
43. Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry 1992;149:1148-1156
44. Jette AM. The Functional Status Index: reliability and validity of a self-report functional disability measure. J Rheumatol Suppl 1987;14(Suppl. 15):15-21
45. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington DC: American Psychiatric Association, 1994
46. Lôo H, Poirier-Littre MF, Theron M, et al. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1997;170:18-22
47. Carrière P, Bonhomme D, Lemperiere T. Amisulpride has a superior benefit/ risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur Psychiatry 2000;15:321-329
48. Colonna L, Saleem P, Dondey-Nouvel L, et al. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol 2000;15:13-22
49. Sechter D, Peuskens J, Fleurot O, et al. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology 2002;27:1071-1081
50. Hwang TJ, Lee SM, Sun HJ, et al. Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan. J Formos Med Assoc 2003;102:30-36
51. Mortimer A, Martin S, Loo H, et al. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol 2004;19:63-69
52. Lecrubier Y, Quintin P, Bouhassira M, et al. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatr Scand 2006;114:319-327
53. Olié JP, Spina E, Murray S, et al. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. Int Clin Psychopharmacol 2006;21:143-151
54. Surguladze S, Patel A, Kerwin RW, et al. Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:517-522
55. Taylor M, Turner M, Watt L, et al. Atypical anti-psychotics in the real world-a naturalistic comparative outcome study. Scott Med J 2005;50:102-106
56. Lambert M, Naber D, Eich FX, et al. Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatr Scand 2007;115:106-113
57. Novick D, Haro JM, Suarez D, et al. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res 2009;108:223-230
58. Novick D, Haro JM, Perrin E, et al. Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Eur Neuropsychopharmacol 2009;19:542-550
59. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085-1097
60. Kusel Y, Laugharne R, Perrington S, et al. Measurement of quality of life in schizophrenia: a comparison of two scales. Soc Psychiatry Psychiatr Epidemiol 2007;42:819-823
61. Bengtsson-Tops A, Hansson L, Sandlund M, et al. Subjective versus interviewer assessment of global quality of life among persons with schizophrenia living in the community: a Nordic multicentre study. Qual Life Res 2005; 14:221-229